Description:
Constitute a category of nonclassical CAIs designed to target oncogenic carbonic anhydrases with anticancer activity.

Text:
Substituted coumarins 
constitute a category of nonclassical CAIs designed specifically to target oncogenic CAs, with 
patented structures owned by Metasignal Therapeutics Inc. 7. 3substituted coumarins have a 
diverse pharmacological space, including anticancer activity by modulating the activity of 
tumorassociated carbonic anhydrases 3,8,9.
